SillaJen, Inc.

Company Profile

Sector

Healthcare

Industry

Biotechnology

Employees

N/A

Website

www.sillajen.com

Country

South Korea

Exchange

KOSDAQ

Founded 2006Seoul, South Korea

SillaJen develops technologies and products using genetic engineering in South Korea. Its clinical pipeline includes Pexa-Vec, which is in phase 2 clinical trial to treat renal cell carcinoma and prostate cancer

In phase 1 clinical trial to treat melanoma and solid tumors. It also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors; and SJ-600 Series and JX-970 to treat solid tumors and is in preclinical trial. Additionally, it operates in biotechnology research industry. Founded in 2006, SillaJen is headquartered in Seoul, South Korea.

Key Stats

52-Week Range

₩1809.00₩5400.00

Beta-0.02

Trailing P/EN/A

Forward P/EN/A

Trailing EPSN/A

Avg Volume

Earnings & Analyst

Next EarningsN/A

EPS EstimateN/A

Target Mean PriceN/A

RecommendationNone

Recommendation MeanN/A

Recent SEC Filings

SEC filings for this ticker are not available yet.